Quarterly share capital audit report filed for September 2026

Compliance View source PDF Explain this filing

REMUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.2%Reaction day

₹975.50

prior close

₹941.55

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-6.0% vs market

On the reaction day the stock moved 6.0 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

+0.8

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-5.2+0.8-6.0

Next day

-5.3+1.0-6.3

+4.8+1.7+3.0

+3.2+0.1+3.2

+4.2+0.8+3.4

+0.5-0.9+1.4

-7.8-4.5-3.4

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Remus Pharmaceuticals has submitted its quarterly Reconciliation of Share Capital Audit Report to NSE as required under SEBI Regulation 76 for the period ending September 30, 2026. The report was signed by practicing company secretary Tapan Shah on October 9, 2026 and filed by Deval Patel, Company Secretary. This is a routine compliance filing with no indication of any change in share capital structure.

Likely market impact

Routine compliance filing, no material impact on shareholders or stock price.